Spectral Platforms, Inc.
Spectral Platforms is dedicated to advancing microbiology and medical technology through innovative solutions. Their mission is to eliminate time-consuming steps in microbiology diagnostics, enabling rapid diagnosis for better health outcomes. They develop proprietary media and testing methods for detecting and characterizing pathogens such as Candida auris, bacteria, and viruses, including applications in space medicine and space-related health research. The company collaborates with regulatory agencies like the FDA and sponsors research projects in microbiology, space medicine, and drug testing.
Industries
Nr. of Employees
small (1-50)
Spectral Platforms, Inc.
1851 Huntington Drive, Duarte CA 91010
Patents
Products
Rapid blood pathogen presence test (30-minute)
A diagnostic test intended to detect presence of pathogenic microorganisms in blood with results within ~30 minutes for triage of patients at risk of sepsis.
Bacterial identification and direct AST (6–8 hour turnaround)
Workflow to subclassify bacteria in clinical samples and deliver antimicrobial susceptibility results reportedly equivalent to CLSI standards, including for polymicrobial samples (reported: ~8 hours blood, ~6 hours urine).
Differential chromogenic media assay for Candida species (96-well)
96‑well plate format differential media for visual colorimetric discrimination of Candida species (including Candida auris) after incubation (36–54 hours), with optional automated plate reader readout.
Rapid blood pathogen presence test (30-minute)
A diagnostic test intended to detect presence of pathogenic microorganisms in blood with results within ~30 minutes for triage of patients at risk of sepsis.
Bacterial identification and direct AST (6–8 hour turnaround)
Workflow to subclassify bacteria in clinical samples and deliver antimicrobial susceptibility results reportedly equivalent to CLSI standards, including for polymicrobial samples (reported: ~8 hours blood, ~6 hours urine).
Differential chromogenic media assay for Candida species (96-well)
96‑well plate format differential media for visual colorimetric discrimination of Candida species (including Candida auris) after incubation (36–54 hours), with optional automated plate reader readout.
Services
Maintenance and QC of fully differentiated human airway epithelial ALI cultures, controlled aerosol exposures, and cellular response assessment.
High-throughput cell viability assays and genotoxicity assays (Ames, MTS, micronucleus, Comet) to assess cytotoxic and mutagenic effects of aerosols or materials.
Characterization of viable pathogen reduction under controlled UV exposures and development of scaling relationships for use in device control software.
Maintenance and QC of fully differentiated human airway epithelial ALI cultures, controlled aerosol exposures, and cellular response assessment.
High-throughput cell viability assays and genotoxicity assays (Ames, MTS, micronucleus, Comet) to assess cytotoxic and mutagenic effects of aerosols or materials.
Characterization of viable pathogen reduction under controlled UV exposures and development of scaling relationships for use in device control software.
Expertise Areas
- Clinical microbiology diagnostics
- Rapid infectious disease testing
- Antimicrobial susceptibility testing (AST)
- In vitro respiratory models (ALI) and aerosol exposure
Key Technologies
- Air-liquid interface (ALI) airway epithelial cell models
- 96‑well plate-based chromogenic assays
- Plate reader automation and data interfacing
- Ames, MTS, micronucleus and Comet assays
News & Updates
The company has started examining ways to use their technology to impact the COVID-19 epidemic.
The company received a patent for their reagent used in microbiology testing.
The USPTO has allowed a patent application related to albumin-based non-covalent complexes.
Spectral Platforms was one of 10 winners in the AMR challenge for their innovative solutions.
The company received US Patent #10,071,141 for their reagent.
The company has started examining ways to use their technology to impact the COVID-19 epidemic.
The company received a patent for their reagent used in microbiology testing.
The USPTO has allowed a patent application related to albumin-based non-covalent complexes.
Spectral Platforms was one of 10 winners in the AMR challenge for their innovative solutions.
The company received US Patent #10,071,141 for their reagent.